Physician profile
John Joseph Mazur
NPI 1659364651
$17,529.76
in general payments reported to CMS, 2019-2025
37 companies · $9,052 in 2025
The $9,052 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $568 · 2021: $732 · 2022: $703 · 2023: $4,167 · 2024: $1,159 · 2025: $9,052.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,299 · Travel and Lodging: $3,742 · Food and Beverage: $3,337.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,298.97 |
| Travel and Lodging | $3,742.24 |
| Food and Beverage | $3,337.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,192.68 | 2025 | |
| Pulmonx Corporation | $3,088.40 | 2022-2025 | Chartis Catheter, Pulmonx Chartis Tablet Console, Zephyr Endobronchial Valve |
| Astrazeneca Pharmaceuticals Lp | $1,183.36 | 2019-2025 | Fasenra, Breztri, Airsupra |
| Actelion Pharmaceuticals US, INC. | $966.26 | 2019-2025 | Opsumit, Uptravi |
| Glaxosmithkline, LLC. | $794.94 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Mallinckrodt Hospital Products INC. | $453.77 | 2020-2024 | Acthar |
| Merck Sharp & Dohme LLC | $412.58 | 2021-2025 | Verquvo, Winrevair, Belsomra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $315.86 | 2019-2025 | Ofev, Jascayd |
| Mylan Specialty L.P. | $282.38 | 2019-2024 | Yupelri |
| Novartis Pharmaceuticals Corporation | $261.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.67 | 2021-2024 | |
| Insmed, INC. | $156.39 | 2021-2025 | Arikayce, Brinsupri |
| Grifols USA, LLC | $148.81 | 2019-2023 | Xembify |
| Genzyme Corporation | $132.86 | 2024 | |
| Harmony Biosciences LLC | $108.12 | 2021-2024 | Wakix |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $102.76 | 2019-2025 | Orenitram, Remodulin, Tyvaso |
| Genentech USA, INC. | $90.89 | 2019-2025 | Xolair |
| Janssen Pharmaceuticals, INC | $87.28 | 2019-2020 | |
| Amgen INC. | $71.26 | 2019-2023 | Tezspire |
| Sunovion Pharmaceuticals INC. | $61.34 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $58.58 | 2023-2024 | Dupixent |
| Medtronic, INC. | $49.30 | 2021-2024 | Illumisite |
| Philips North America LLC | $42.75 | 2019 | |
| Mallinckrodt Enterprises LLC | $42.61 | 2019 | |
| Covidien Lp | $40.06 | 2019-2020 | |
| Biodelivery Sciences International, INC. | $30.16 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $27.84 | 2025 | Glassia |
| Advanced Respiratory, INC | $22.11 | 2020 | |
| Medtronic Vascular, INC. | $21.38 | 2019 | |
| Veran Medical Technologies, INC. | $20.15 | 2020 | |
| Pfizer INC. | $18.00 | 2023 | |
| Lilly USA, LLC | $16.28 | 2025 | Zepbound |
| Lantheus Medical Imaging, INC. | $15.02 | 2019 | |
| Ethicon INC. | $14.00 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $12.95 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.94 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Mazur listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.